Marshall Wace, LLP Rapt Therapeutics, Inc. Transaction History

Marshall Wace, LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$11.28 - $25.46 $249,581 - $563,327	22,126 New	22,126 $549,000
Q1 2022 May 16, 2022	SELL	$17.02 - $40.22 $1.86 Million - $4.4 Million	-109,470 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$29.5 - $39.5 $313,408 - $419,648	-10,624 Reduced 8.85%	109,470 $4.02 Million
Q3 2021 Nov 15, 2021	BUY	$29.86 - $39.47 $1.27 Million - $1.68 Million	42,552 Added 54.88%	120,094 $3.73 Million
Q2 2021 Aug 13, 2021	BUY	$17.99 - $40.02 $1.39 Million - $3.1 Million	77,542 New	77,542 $2.47 Million

105

27.1M

26.7K

2.4K

Ticker RAPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,656,600
Market Cap $35.6M
Description
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.